登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603102 证券简称：百合股份 公告编号：2025-021 威海百合生物技术股份有限公司 关于以集中竞价交易方式回购公司股份 的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 一、回购股份的基本情况 公司于2024年8月8日召开第四届董事会第九次会议，审议通过了《关于以集中竞价交易方式回购公司股 份方案的议案》，同意公司以自有或自筹资金以集中竞价交易方式回购部分公司股份，本次回购股份将 在未来适宜时机全部用于员工持股计划或股权激励，回购价格不超过人民币42元/股（含），回购资金 总额不低于人民币3,000万元（含），不超过人民币6,000万元（含），回购期限为自董事会审议通过本 次回购方案之日起12个月内，具体内容详见公司在上海证券交易所网站（www.sse.com.cn）披露的《关 于以集中竞价交易方式回购公司股份方案的公告》（公告编号：2024-025）和《关于以集中竞价交易方 式回购公司股份的回购报告书》（公告编号：2024-02 ...

威海百合生物技术股份有限公司 关于召开 2024 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 会议召开时间：2025 年 6 月 11 日（星期三）下午 15:00-16:00 证券代码：603102 证券简称：百合股份 公告编号：2025-022 ? 会议召开地点：全景网"投资者关系互动平台"（http://ir.p5w.net） ? 会议召开方式：网络互动方式 ? 投 资 者 可 于 2025 年 6 月 10 日 （ 星 期 二 ） 16:00 前 通 过 公 司 邮 箱 suntongbo@sohu.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 威海百合生物技术股份有限公司（以下简称"公司"）已于 2025 年 4 月 15 日发布公司 2024 年年度报告，为便于广大投资者更全面深入地了解公司 2024 年度经营成果、财务状况，公司计划于 2025 年 6 月 11 日下午 15:00-16:00 举行 一、说明会类型 本次投资者说明会以网络互动形 ...

威海百合生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603102 证券简称：百合股份 公告编号：2025-021 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等相关规定，公司在回购股份期间，应当在每个月的前 3 个交易 日内公告截至上月末的回购进展情况。现将公司截至 2025 年 5 月 31 日的回购股 份进展情况公告如下： 截至 2025 年 5 月 31 日，公司通过上海证券交易所系统以集中竞价交易方式 回购公司 A 股普通股股票 92,400 股，占公司当前总股本的比例为 0.14%，回购的 最高成交价格为人民币 35.00 元/股，最低成交价格为人民币 34.64 元/股, 支付的资 金总额为人民币 3,218,092 元（不含印花税、交易佣金等交易费用）。 上述回购股份进展符合相关法律法规的规定及公司回购股份方案的要求。 三、其他事项 | 回购方案首次披 ...

证券代码：603102 证券简称：百合股份 公告编号：2025-022 威海百合生物技术股份有限公司 重要内容提示： 关于召开 2024 年度业绩说明会的公告 投资者可于 2025 年 6 月 10 日（星期二）16:00 前通过公司邮箱 suntongbo@sohu.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 威海百合生物技术股份有限公司（以下简称"公司"）已于 2025 年 4 月 15 日发布公司 2024 年年度报告，为便于广大投资者更全面深入地了解公司 2024 年度经营成果、财务状况，公司计划于 2025 年 6 月 11 日下午 15:00-16:00 举行 2024 年度业绩说明会，就投资者关心的问题进行交流。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一） ...

保健品之新：新品类 悦己特征突出，美容养颜类高景气。颜值经济驱动下，美容养颜、身材管理、运动健身、护发固发此类 与"颜值经济"相关的功效品类遥遥领先，在抖音TOP20的商品中，占据超49%的市场份额，同时护肝、 润喉赛道增速亮眼，三高心血管健康、骨骼健康市场体量稳固。营养健康食品零食化趋势显著，年轻消 费者更倾向即食软糖、冲泡粉剂等形态，非蓝帽子产品接受度提升，功能性食品销量占比持续增长。抗 衰老赛道扩容加速，麦角硫因因超强抗氧化能力成为出圈爆点，跨境品牌充分受益。 保健品之新：新群体 消费群体年轻化与下沉化趋势明显，女性、Z世代及宠物主成为核心增量人群，其中31-40岁消费者占比 最高，24-30岁增速最快，下沉市场消费者占比提升，低线城市成为高潜用户。 中信建投（601066）发布研报称，国内保健品市场正经历结构性变革，渠道、品类与消费群体呈现显著 分化，新消费特征正在驱动行业价值重估。线上渠道凭借高渗透率与灵活性持续扩张，短视频、跨境电 商及私域平台成为增长引擎，而传统药店受政策与客流影响持续萎缩。消费群体年轻化与下沉化趋势明 显，女性、Z世代及宠物主成为核心增量人群。保健品公司通过跨境布局、产品创新及 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The report indicates that the liquor industry is in a bottoming phase, with signs of stabilization in fundamentals. The high-end liquor sector is expected to see a recovery in demand and valuation in the second half of the year. The report emphasizes focusing on leading regional high-end liquor companies while waiting for demand recovery and valuation repair to resonate [3][11] - The report highlights significant opportunities in the yellow wine sector, which is experiencing a revival driven by changing consumer preferences towards healthier and lighter drinking options. The report notes that yellow wine is well-positioned to cater to the "self-consumption" trend and is gradually breaking the stereotype of being a traditional drink for older consumers [4][12] Summary by Sections Weekly Insights - From May 26 to May 30, the food and beverage index declined by 1.1%, ranking 24th among 28 sub-industries, performing in line with the CSI 300 index. The soft drink (+9.3%), other alcoholic beverages (+7.1%), and beer (+3.2%) sectors showed relatively strong performance [3][11][13] Market Performance - The liquor industry continues to show weak recovery, with terminal demand remaining sluggish. The report attributes this to slow consumer recovery and a reduction in business banquet scenarios. The recent re-emphasis on the prohibition of alcohol consumption in government settings has raised market concerns, but the actual impact is considered limited due to already low levels of government consumption [3][11][12] Upstream Data - As of May 20, the auction price for whole milk powder was $4,332 per ton, a year-on-year increase of 27.1%. Meanwhile, the domestic fresh milk price was 3.1 yuan per kilogram, showing a year-on-year decrease of 8.9%. The report suggests that domestic milk prices are still on a downward trend in the short term [21][24] Liquor Industry News - The report mentions that the Guizhou Moutai (Walking Series) is set to launch soon, and during the recent promotional event, the overall sales of liquor exceeded 300 million yuan within 12 hours, marking a significant increase compared to the previous year [44][45]

Group 1 - Huiyu Pharmaceutical's subsidiary received drug registration certificate for Carboxymethyl Sodium Injection, which is used for treating bleeding diseases in various medical fields [1] - Baihe Co., Ltd. announced a plan for a director to reduce holdings by up to 424,000 shares, representing 0.6625% of the total share capital [1] - Kingood Co., Ltd. received a notification from a global leading automaker for a wheel project, expected to start mass production in 2026 with a lifecycle of 10 years [1][2] Group 2 - Wanhua Chemical plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum repurchase price of 99.36 yuan per share [2] - Warner Pharmaceutical's subsidiary received approval for Acetylcysteine raw material drug, primarily used for treating respiratory diseases [3] - ST Mingcheng plans to publicly transfer 45% equity of its subsidiary, aiming to optimize asset structure [4] Group 3 - Qixia Construction announced a plan to reduce up to 31.5 million shares, accounting for 3% of total share capital [5][6] - Zhejiang Rongtai intends to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - Yuandong Biological received drug registration for Chloral Hydrate Enema, used for sedation and seizure control in children [9] Group 4 - Jiemai Technology's subsidiary signed a strategic cooperation agreement with a solid-state battery company to produce high-safety composite conductive materials [10] - Xianju Pharmaceutical received drug registration for Progesterone Soft Capsules, used for treating functional disorders due to luteal deficiency [11] - Lanhua Kecai's subsidiary reported a temporary production halt, with the resumption date yet to be determined [13] Group 5 - Sinopharm Modern's subsidiary received drug registration for Tocilizumab Tablets, used for treating rheumatoid arthritis and other conditions [15] - Shanghai Bank announced the resignation of its vice president due to organizational adjustments [17] - Shanghai Pharmaceutical's Ephedrine Injection passed the consistency evaluation for generic drugs [19] Group 6 - Rundu Co., Ltd. received drug registration for Amlodipine and Olmesartan Tablets, aimed at treating hypertension [21] - Zhong'an Technology announced that 61 million shares held by its controlling shareholder will be auctioned [23] - Shanghai Washba plans to purchase patent assets and establish two subsidiaries focused on hydrogen energy and solid-state battery technologies [25] Group 7 - Nuo Cheng Jianhua's new drug Tafasitamab received approval for treating relapsed/refractory diffuse large B-cell lymphoma [26] - Benli Technology plans to use up to 200 million yuan of idle funds for cash management and financial investments [28] - Taiji Co., Ltd. intends to use 60 million yuan of idle funds to purchase financial products [29] Group 8 - Haishi Co. announced that its innovative drug Anreke Fen Injection received drug registration for treating postoperative pain [32] - Yulong Co. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [36] - Weifu High-Tech plans to establish a joint venture with Shanghai Baolong Automotive Technology [38] Group 9 - Xichang Electric Power expects a net profit reduction of approximately 5.4 million yuan due to adjustments in the time-of-use electricity pricing mechanism [39] - Alter signed a contract worth 6.8 billion yen for the development and procurement of large truck EV kits [41] - Zhonglian Heavy Industry plans to acquire controlling stakes in its financing leasing subsidiary through public bidding [42] Group 10 - Sanyou Medical's executive plans to reduce holdings by up to 1.44% of the company's shares [43] - Hangyang Co. plans to establish a subsidiary for large modular cryogenic equipment manufacturing with an estimated investment of 557 million yuan [44] - FAW Fuwi received a notification for a dashboard project from a well-known new energy brand, with total sales expected to reach 1.06 billion yuan [45]

证券代码：603102 证券简称：百合股份 公告编号：2025-020 威海百合生物技术股份有限公司 董事减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、减持主体的基本情况 上述减持主体无一致行动人 1 预披露期间，若公司股票发生停牌情形的，实际开始减持的时间根据停牌时间相 应顺延。 (一)相关股东是否有其他安排 □是 √否 重要内容提示： 董事持股的基本情况 截至本公告披露之日，董事王文通先生持有公司股份 1,697,518 股，占公司 总股本的 2.65%，上述股份全部来源于公司首次公开发行股票前已持有的股份。 减持计划的主要内容 王文通计划通过集中竞价方式减持公司股份不超过 424,000 股，不超过公司 总股本的 0.6625%，本减持计划在本公告披露之日起十五个交易日后的三个月内 进行（窗口期不减持）。若在减持计划实施期间公司发生送股、资本公积金转增 股本等股份变动事项，王文通可以根据公司股本变动情况对减持计划进行相应调 整。 | 股东名称 | 王文通 | | | --- | --- ...

百合股份（603102）公告，董事王文通计划通过集中竞价方式减持公司股份不超过42.4万股，不超过公 司总股本的0.6625%。 ...

Investment Rating - The report maintains an "Increase" rating for the pet industry, indicating a positive outlook for the sector [5]. Core Insights - The pet industry in China has surpassed 300 billion yuan in consumer spending, showing a trend of simultaneous growth in both volume and price. The urban consumption market is projected to grow by 7.5% in 2024, reaching 300.2 billion yuan [1][2]. - The consumption market for dogs is expected to reach 155.7 billion yuan, with a slight increase of 4.6%, while the cat market is projected to grow by 10.7% to 144.5 billion yuan [1]. - The number of pets in China is anticipated to reach 124.11 million in 2024, reflecting a year-on-year growth of 2.1% [1]. - Average annual spending per pet dog is estimated at 2,961 yuan, up by 3.0%, and for cats, it is 2,020 yuan, increasing by 4.9% [1]. - The food market remains the largest segment, accounting for 52.8% of total consumption, followed by the medical market at 28.0% [1]. Summary by Sections Market Trends - The emotional companionship attributes of pets align with trends of single living, declining birth rates, and an aging population, which are expected to drive incremental consumer demand [2]. - There is a growing preference for domestic staple food brands and smart pet products, alongside increased consumer focus on product quality and value [2]. - Pet owners are increasingly concerned about their pets' physical and mental health, highlighting a need for reliable veterinary services [2]. Investment Opportunities - The report suggests focusing on various investment opportunities within the pet sector, including companies involved in pet food, supplies, healthcare, and technology [3][8].